title: Phenotypic expression of a novel C282Y/R226G compound heterozygous state in HFE hemochromatosis: molecular dynamics and biochemical studies.
abstract: Most adults affected with hereditary hemochromatosis are homozygous for a single point mutation of HFE (p.Cys282Tyr). Apart from the compound heterozygous state for the p.Cys282Tyr mutant and the widespread p.His63Asp variant allele, other rare HFE mutations can be found in trans and may have clinical impact. In the present report we describe the structural and functional consequences of a new mutation, namely the p.Arg226Gly which was inherited in trans with the p.Cys282Tyr allele in a patient affected with a mild iron overload. Because the R226G substitution is located in the vicinity of the normal Cys225S-S282Cys disulfide bond we initially investigated the structure of the variant by molecular dynamics techniques in order to estimate the effect of the mutation on the global structure of HFE domain α3. We found that the solvation free energy, hydrophobicity and formation of salt bridges are slightly modified with the global secondary structure of the α3 domain being conserved. In a previous paper, we demonstrated that the Q283P substitution leads to the loss of the normal Cys225S-S282Cys disulfide bridge. Similar to the Q283P substitution, the R226G substitution does not substitute a residue directly involved in the formation of the disulfide bridge. However, unlike the p.Gln283Pro variant which destroyed the normal disulfide bridge, the R226G mutation does not affect the normal Cys225S-S282Cys bridge. Furthermore based on cell line studies we clearly show that the mutation does not prevent cell surface localization, β2-microglobulin association and binding to transferrin receptor 1. This new compound heterozygous phenotype is very close to those of the C282Y/H63D compound heterozygous patients who display the biochemical hemochromatosis phenotype but with lower body iron stores than C282Y homozygotes. Our results do not exclude unknown genetic and/or metabolic factors that may act synergistically to increase the ferritin level.
authors: Laboratoire des Glucides, CNRS FRE 3517, Université de Picardie Jules Verne, Amiens 80037 Cedex 1, France.
authors: Christine
authors: C
authors: Cézard
authors: Amrathlal
authors: A
authors: Rabbind Singh
authors: Gérald
authors: G
authors: Le Gac
authors: Isabelle
authors: I
authors: Gourlaouen
authors: Claude
authors: C
authors: Ferec
authors: Jacques
authors: J
authors: Rochette
mesh_terms: D000328:Adult; D000483:Alleles; D015703:Antigens, CD / Q000235:genetics / Q000378:metabolism; D004220:Disulfides / Q000737:chemistry; D015870:Gene Expression; D006432:Hemochromatosis / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D000071020:Hemochromatosis Protein; D006579:Heterozygote; D015395:Histocompatibility Antigens Class I / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism; D006720:Homozygote; D006801:Humans; D057927:Hydrophobic and Hydrophilic Interactions; D008297:Male; D008565:Membrane Proteins / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism; D008875:Middle Aged; D056004:Molecular Dynamics Simulation; D009154:Mutation; D011485:Protein Binding; D017433:Protein Structure, Secondary; D017434:Protein Structure, Tertiary; D011990:Receptors, Transferrin / Q000235:genetics / Q000378:metabolism; D012720:Severity of Illness Index; D013816:Thermodynamics; D001613:beta 2-Microglobulin / Q000235:genetics / Q000378:metabolism
chemical_list: D015703:Antigens, CD; C068126:CD71 antigen; D004220:Disulfides; C103673:HFE protein, human; D000071020:Hemochromatosis Protein; D015395:Histocompatibility Antigens Class I; D008565:Membrane Proteins; D011990:Receptors, Transferrin; D001613:beta 2-Microglobulin
keywords: Compound heterozygosity; Disulfide bridge; HFE(R226G) variant; Hemochromatosis; Molecular dynamics